Acquirer
Ipsen
Ipsen appears as the named buyer in 4 recorded transactions between 2017 and 2023, most often in healthcare & life sciences. 1 of those was bought from a private equity seller, which makes this a buyer that funds in the sector actually exit to.
Record
What Ipsen has bought
Every recorded transaction where Ipsen is the named buyer. Most private deals never disclose a consideration, so a dash is the normal case rather than a gap in the record.
| Target | Sector | Sold by | Date | Consideration |
|---|---|---|---|---|
| Albireo | Healthcare & Life Sciences | — | 2023-01-09 | $952m |
| Epizyme | Healthcare & Life Sciences | Bay City Capital PE | 2022-06-27 | $247m |
| Sanofi SA - Consumer Healthcare Products | Healthcare & Life Sciences | Sanofi | 2017-02-13 | $94m |
| Merrimack Pharmaceuticals | Healthcare & Life Sciences | Merrimack Pharmaceuticals | 2017-01-08 | $575m |
Compiled from an archive of 10,204 recorded transactions. This is a record of deals that were reported, not a complete history of what this company has bought, and nothing here is represented as being for sale.
Also buying
Comparable buyers
Other companies acquiring in healthcare & life sciences.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Are you an investor?
Register your mandate and we will send matching opportunities as they arise.
Register a mandateTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.